Search Results
10
Everything
Search Filters
Organization
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
February 27, 2020 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
February 11, 2020 19:06 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
February 10, 2020 16:06 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 27, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2019 13:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
November 21, 2019 06:00 ET
|
Xeris Pharmaceuticals, Inc.
MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program...
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
November 07, 2019 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 01, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
October 01, 2019 08:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 27, 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...